A cell line of plasma cells with high ammonia (NH3) production (KHM-4) was established from a patient with multiple myeloma complicated by hyperammonemia and abnormal serum concentrations of amino acids. Surface marker studies of KHM-4 cells showed that the cells were positive for cytoplasmic immunoglobulins (IgA kappa), HLA-DR, and T 10. Secretion of ammonia by the KHM-4 cells was detected by the addition of L-glutamine and L-arginine into the culture medium of amino acid-free RPMI 1640. In the presence of L-glutamine, KHM-4 cells secreted a greater amount of ammonia than the T cell line, CEM. However, production of ammonia by L-arginine was not observed in other cell lines. These observations provide evidence for the existence of a peculiar amino acid metabolism in the myeloma cells causing hyperammonemia and serum amino acid disturbance. (Internal Medicine 31: 339-343, 1992) 
Introduction
Hyperammonemia occurs in a diverse range of disorders such as liver failure (1, 2), Reye's syndrome (3), inborn errors of urea synthesis (4), homocitrullinuria syndrome (5), lysinuric protein intolerance (6) , and transient hyperammonemia of the newborn (7) . It may also occur as a complication of urinary tract infection (8) , asparaginase therapy (9) , valproic acid therapy (10) , and systemic carnitine deficiency (ll) . Recently, we encountered and reported two patients with multiple myeloma who had hyperammonemia, serum amino acid disturbances, and disturbance of consciousness (12) . Malignant plasma cells have proved to be very difficult to establish; however, we established a myeloma cell line (KHM-4) from one patient with hyperammonemia. In this study, we analyzed the mechanism of hyperammonemia using KHM-4 cells.
Materials and Methods
Case report. A 51-year-old female with IgA kappa type multiple myeloma was readmitted to our hospital with a huge plasmacytoma of the right chest wall in September 1988. Despite intensive chemotherapy, her condition did not improve and she developed hyperam monemia (100-160 /ig/dl) and somnolence. The serum levels of valine, leucine, isoleucine, threonine, cystine, glutamine, arginine, histidine, tryptophan, citrulline, and ornithine were significantly low. However, the concentrations of glycine and aspartic acid were high. Her somnolence transiently improved after intensive chemotherapy, but she died of complications related to pleural effusion secondary to myeloma cells in May 1989. Autopsy revealed almost normal liver histology (12) . Cell culture. Heparinized pleural effusion fluid from the patient was layered onto the Ficoll-Conray (specific gravity, 1.078), and centrifuged at 400g for 30 minutes. The interphase cells, which consisted almost entirely of myeloma cells, were collected and seeded into culture plates at approximately 106cells/ml after washing with complete medium. In primary culture and the early passages, RPMI 1640 medium containing 20% fetal calf serum (FCS) was used, and when the cells began to grow steadily, the medium was changed to RPMI 1640 containing 10% FCS. Throughout the study, the similar to the level prior to culture. A slight increase in ammonia by L-cystine (262 ± 69/^g/dl), a significant increase by L-arginine (338 ± 55 //g/dl), and a marked in crease by L-glutamine (1,393 ± 51 jug/dl) were detected; however, other amino acids such as asparagine, aspartic acid, glutamic acid glycine, histidine, hydroxyproline, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine did not induce the secretion of ammonia (Fig. 3) . A smaller amount of ammonia secretion was also detected in the culture medium of CEM cells with the addition of L-glutamine (Fig. 4) . In the presence of L-arginine, no increase of ammonia was detected in the culture medium of CEM cells (Fig. 4) and cell lines, KHM-1A, KHM-2B, and KMS-12-PE (data not shown). These data indicate that the metabolism of arginine by KHM-4 cells is qualitatively different from that of other cell lines. Figure 5 shows the dose effect of L-glutamine and L-arginine on the accumulation of ammonia. Accumu lation of ammonia by KHM-4 cells was detected during
Hours of culture 
Discussion
Hyperammonaemia is mainly seen in hepatic failure (1, 2) and congenital metabolic disorders (4-6), however, there was no evidence of liver dysfunction or an occult congenital metabolic disorder in this patient, and the liver was found to be almost normal at autopsy (12). Tsunoda et al. have reported four cases of multiple myeloma with hyperammonemia and disturbance of consciousness in which liver function was within the normal range (16) . The mechanism of hyperammonemia was not known, but they suggested that the plasma of some patients with multiple myeloma contained unidentified factors which increased the plasma ammonia concentration. We de monstrated that KHM-4 cells established from the patient with multiple myeloma and hyperammonemia secreted ammonia in the presence of L-glutamine and L-arginine.
The cause of hyperammonemia in this patient seems to be directly related to the myeloma cells, due to the production of ammonia by KHM-4 cells in the presence of normal serum concentrations of L-glutamine and L-arginine. It is suggested that serum amino acid alterations are a more important factor than hyperammonemia in the induction of disturbance of consciousness in hepatic failure. In particular, the decrease in branched-chain amino acids (leucine, isoleucine, and valine) and the increase in aromatic amino acids (phenylalanine and tyrosine) which results in a low Fischer ratio, is regarded as the most important factor. Serum amino acid al terations and a low Fischer ratio (1.29; normal range 2.6-4.3) were detected in our patient. The branched chain amino acids had a very low concentration, but the aromatic amino acids were not increased. However, the concentration of tyrosine was low. We demontrated that the arginine metabolism of KHM-4 cells was completely different from that of other cell lines. KHM-4 may become a useful tool for the biochemical analysis of hyperammonemia and serum amino acid alterations in multiple myeloma. Supported in part by Grant-in-Aid for Cancer Research (61-2) from the Ministry of Health and Welfare, and a grant (01770902) from the Ministry of Education, Science, and Culture of Japan
